Shawn Tomasello Biography and Net Worth

Ms. Tomasello joined Cabaletta’s Board of Directors in July 2023. She brings over 35 years of experience in the life sciences industry and most recently served as Chief Commercial Officer of Kite Pharma (subsequently Kite, a Gilead Company), where she led the global launch and commercialization of Yescarta™ (axicabtagene ciloleucel), the first approved chimeric antigen receptor (CAR) T therapy for the treatment of adult patients with relapsed or refractory non-Hodgkin lymphoma. Prior to joining Kite, Ms. Tomasello served as Chief Commercial Officer at Pharmacyclics, Inc, now part of AbbVie, where she led commercial and medical affairs activities for Imbruvica®. Previously, she held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology, in which she oversaw over $4 billion in product revenues. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for five brands encompassing 11 indications. Prior to this, she was National Director of Hematology for Rituxan® at Genentech, representing the most significant portion of the company’s product revenue during her tenure. Earlier in her career, Ms. Tomasello held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. She currently serves on the Boards of 4D Molecular Therapeutics, AlloVir and Gamida Cell Ltd. Ms. Tomasello holds a B.S. degree in marketing from the University of Cincinnati and an M.B.A. from Murray State University, KY.